Compare Globus Medical Inc. Class A Common Stock (GMED) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Workiva Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Workiva Inc trades at $72.22 (market cap $3.95B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.6× Workiva Inc's market cap, and Workiva Inc is more actively traded (612,757 versus 1,108,124). Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Workiva Inc for 20 Days on average.
| GMED | WK | |
|---|---|---|
Market Cap | $10.25B | $3.95B |
Volume | 1,108,124 | 612,757 |
Sector | Health | Technology |
52-Week High | $96.82 | $93.31 |
52-Week Low | $58.33 | $44.31 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $9.76B | $3.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
WK trades at $72.50, down 0.74% on the day, with strong technical momentum showing bullish moving averages and support at $72. The company demonstrates robust revenue growth, reaching $966M in 2026 with net income turning positive at $47M, while consistently beating earnings expectations. Recent product innovations in AI and regulatory technology highlight ongoing business development.
The outlook remains positive with 89% analyst buy ratings and an $86 price target, though elevated valuation multiples and execution risks in competitive markets warrant caution. Upside potential exists if earnings growth continues, but investors should monitor margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
